Data / Drug companies / PD-Rx Pharmaceuticals, Inc.
PD-Rx Pharmaceuticals, Inc.: 496 products in the FDA NDC directory, labeler code 72789
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
PD-Rx Pharmaceuticals, Inc. (labeler code 72789) lists 496 products in the FDA National Drug Code Directory, covering 179 finished drugs by generic name. By type: 479 prescription drugs, 17 over the counter drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on October 9, 2026.
The request: Watch PD-Rx Pharmaceuticals, Inc. (FDA labeler code 72789): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 72789
- Products in commercial distribution
- 496
- Packages
- 1,119
- Finished drugs by generic name
- 179
- Prescription products
- 479
- Over the counter products
- 17
- Controlled substance products
- Schedule IV 30, Schedule V 1
- Flagged as original packager
- 14 of 14 products that carry the flag
- Started marketing in the last 12 months
- 18
- Products with a marketing end date set
- 14
- Earliest marketing start
- January 12, 1973
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 479 | 96.6% |
| Over the counter monograph drugs | 10 | 2% |
| New drug applications (NDA) | 4 | 0.8% |
| Other unapproved drugs | 3 | 0.6% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 479 | 96.6% |
| Over the counter drugs | 17 | 3.4% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet | 213 | 42.9% |
| Tablet, film coated | 145 | 29.2% |
| Capsule | 68 | 13.7% |
| Tablet, extended release | 24 | 4.8% |
| Tablet, film coated, extended release | 15 | 3% |
| Tablet, coated | 7 | 1.4% |
| Tablet, delayed release | 6 | 1.2% |
| Capsule, delayed release | 6 | 1.2% |
| Capsule, extended release | 3 | 0.6% |
| Kit | 3 | 0.6% |
| Capsule, gelatin coated | 2 | 0.4% |
| Capsule, liquid filled | 2 | 0.4% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Glipizide | 72789-580 | Tablet | Generic drugs (ANDA) | October 9, 2026 |
| Glipizide | 72789-579 | Tablet | Generic drugs (ANDA) | October 9, 2026 |
| Anastrozole | 72789-575 | Tablet, film coated | Generic drugs (ANDA) | June 22, 2026 |
| Hyoscyamine Sulfate | 72789-563 | Tablet, orally disintegrating | Other unapproved drugs | April 16, 2026 |
| Haloperidol | 72789-569 | Tablet | Generic drugs (ANDA) | April 8, 2026 |
| Haloperidol | 72789-568 | Tablet | Generic drugs (ANDA) | April 8, 2026 |
| Haloperidol | 72789-567 | Tablet | Generic drugs (ANDA) | April 8, 2026 |
| Haloperidol | 72789-566 | Tablet | Generic drugs (ANDA) | April 8, 2026 |
| Haloperidol | 72789-559 | Tablet | Generic drugs (ANDA) | April 8, 2026 |
| Haloperidol | 72789-558 | Tablet | Generic drugs (ANDA) | April 8, 2026 |
| Metoprolol tartrate | 72789-555 | Tablet | Generic drugs (ANDA) | March 12, 2026 |
| Ibuprofen | 72789-600 | Tablet, film coated | Generic drugs (ANDA) | December 15, 2025 |
| Ibuprofen | 72789-598 | Tablet, film coated | Generic drugs (ANDA) | December 15, 2025 |
| Ibuprofen | 72789-590 | Tablet, film coated | Generic drugs (ANDA) | December 15, 2025 |
| Ibuprofen | 72789-584 | Tablet, film coated | Generic drugs (ANDA) | December 15, 2025 |
| Ibuprofen | 72789-565 | Tablet, film coated | Generic drugs (ANDA) | December 15, 2025 |
| Sevelamer carbonate | 72789-562 | Tablet | Generic drugs (ANDA) | December 15, 2025 |
| Dexamethasone | 72789-534 | Tablet | Generic drugs (ANDA) | November 21, 2025 |
| Dicyclomine hydrochloride | 72789-546 | Capsule | Generic drugs (ANDA) | September 30, 2025 |
| Dicyclomine hydrochloride | 72789-522 | Capsule | Generic drugs (ANDA) | September 30, 2025 |
| Metformin hydrochloride | 72789-561 | Tablet, film coated | Generic drugs (ANDA) | August 25, 2025 |
| Metformin hydrochloride | 72789-551 | Tablet, film coated | Generic drugs (ANDA) | August 25, 2025 |
| Prochlorperazine maleate | 72789-518 | Tablet, film coated | Generic drugs (ANDA) | July 28, 2025 |
| Prochlorperazine maleate | 72789-517 | Tablet, film coated | Generic drugs (ANDA) | July 28, 2025 |
| Fluoxetine | 72789-554 | Capsule | Generic drugs (ANDA) | July 11, 2025 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.